Catalyst Event
Medy-Tox Inc (086900) · Other
From Akros Korea Shareholder Return High Dividend Index (AKSRHD)
4/30/2026, 12:00:00 AM
On April 30, 2026, Medy-Tox's affiliate Numeco announced it had received product approval for its botulinum toxin 'Newlux' from the Ministry of Health of Ukraine, marking its third entry into a European country.
Korean Translation
2026년 4월 30일, 계열사 뉴메코가 우크라이나 보건부로부터 보툴리눔 톡신 제제 '뉴럭스'의 품목허가를 획득했다고 발표함. 이는 세 번째 유럽 국가 진출임.
Related Recent Events
Dongsung Finetec Co Ltd (033500) · Earnings Release
Q1 2026 earnings release scheduled.
5/18/2026, 12:00:00 AM
Kepco Plant Service & Engineering Co Ltd (051600) · Earnings Release
1Q 2026 earnings release scheduled for May 18, 2026. Analysts forecast a recovery in performance compared to the previous quarter, which is expected to have a medium impact on the stock price.
5/18/2026, 12:00:00 AM
Binggrae Co Ltd (005180) · Earnings Release
Q1 2026 earnings release on 2026-05-18; market analysts estimate typical quarterly results will have a low price impact expected.
5/18/2026, 12:00:00 AM
COWAY Co Ltd (021240) · Earnings Release
Q1 2026 earnings release scheduled for 2026-05-17. Hanwha Investment & Securities analysts forecast revenue of KRW 1.34T (+13.8% YoY) and operating profit of KRW 251.9B (+19.3% YoY) estimated. Medium importance estimated as earnings typically drive significant price movement. Scheduled.
5/17/2026, 12:00:00 AM
Daishin Securities Co Ltd (003540) · Earnings Release
Daishin Securities is scheduled to release its Q1 2026 earnings report on May 15, 2026. Earnings releases typically cause significant price volatility, justifying a medium importance estimate scheduled.
5/15/2026, 12:00:00 AM
Samsung Life Insurance Co Ltd (032830) · Earnings Release
Q1 2026 earnings release scheduled for 2026-05-14. Medium importance is estimated based on significant projected profit growth, and analysts forecast a consolidated net profit of KRW 751.8 billion, an 18% YoY increase, forecasted.
5/14/2026, 12:00:00 AM